Literature DB >> 34950411

Clinical Problem-Solving: Lower Extremity Weakness & Paresthesia in an Immunocompromised Patient With a Complex Cancer History.

Brian Stamm1, Margaret Yu1, Jennifer Adrissi1, Sarah M Brooker1, Nicholas E F Hac1, Shubadra Priyadarshini1, Karan Dixit1.   

Abstract

We present a case of new onset bilateral lower extremity weakness, paresthesia, urinary retention and bowel incontinence in a 51-year-old man. He had a complicated history of acute myelogenous leukemia with known central nervous system (CNS) and leptomeningeal involvement status post allogenic stem cell transplant complicated by chronic graft versus host disease (GVHD). We review the differential diagnosis as the physical exam and diagnostic results evolved. We also provide a review of the relevant literature supporting our favored diagnosis, as well as other competing diagnoses in this complicated case. The ultimate differential diagnosis included viral myelitis, treatment-related myelopathies, and CNS GVHD. The case provides a sobering reminder that even with an appropriate diagnostic workup, some cases remain refractory to therapeutic efforts. It also underscores the importance of a sensitive neurologic exam, given the significant clinico-radiological delay, and reviews the complex differential diagnosis for myelopathy.
© The Author(s) 2021.

Entities:  

Keywords:  clinical problem-solving; myelopathy; transverse myelitis

Year:  2021        PMID: 34950411      PMCID: PMC8689523          DOI: 10.1177/19418744211017396

Source DB:  PubMed          Journal:  Neurohospitalist        ISSN: 1941-8744


  15 in total

1.  Evidence-based guideline: clinical evaluation and treatment of transverse myelitis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Authors:  T F Scott; E M Frohman; J De Seze; G S Gronseth; B G Weinshenker
Journal:  Neurology       Date:  2011-12-07       Impact factor: 9.910

2.  Neurotoxicity of intra-CSF liposomal cytarabine (DepoCyt) administered for the treatment of leptomeningeal metastases: a retrospective case series.

Authors:  Marc C Chamberlain
Journal:  J Neurooncol       Date:  2012-04-27       Impact factor: 4.130

Review 3.  Immunopathogenesis of acute transverse myelitis.

Authors:  Douglas A Kerr; Harold Ayetey
Journal:  Curr Opin Neurol       Date:  2002-06       Impact factor: 5.710

4.  Acute myeloid leukemia presenting with complete paraplegia and bilateral total blindness due to central nervous system involvement.

Authors:  Kohta Asano; Hidetaka Wakabayashi; Naohisa Kikuchi; Hironobu Sashika
Journal:  Spinal Cord Ser Cases       Date:  2016-04-07

5.  Cytomegalovirus associated longitudinally extensive transverse myelitis and acute hepatitis in an immunocompetent adult.

Authors:  Wai Foong Hooi; Abhishek Malhotra; James Pollard
Journal:  J Clin Neurosci       Date:  2018-02-01       Impact factor: 1.961

Review 6.  Cytomegalovirus-associated acute transverse myelitis in immunocompetent adults.

Authors:  C A Fux; S Pfister; F Nohl; S Zimmerli
Journal:  Clin Microbiol Infect       Date:  2003-12       Impact factor: 8.067

7.  Evaluation of idiopathic transverse myelitis revealing specific myelopathy diagnoses.

Authors:  Nicholas L Zalewski; Eoin P Flanagan; B Mark Keegan
Journal:  Neurology       Date:  2017-12-15       Impact factor: 9.910

8.  Acute aseptic meningitis due to intravenous immunoglobulin therapy in Guillain-Barré syndrome.

Authors:  Rajendra Singh Jain; Sunil Kumar; Rakesh Aggarwal; Jagdeesh Chandra Kookna
Journal:  Oxf Med Case Reports       Date:  2014-10-29

9.  Case report: Central nervous system involvement of human graft versus host disease: Report of 7 cases and a review of literature.

Authors:  Mathilde Ruggiu; Wendy Cuccuini; Karima Mokhtari; Véronique Meignin; Régis Peffault de Latour; Marie Robin; Flore Sicre de Fontbrune; Aliénor Xhaard; Gérard Socié; David Michonneau
Journal:  Medicine (Baltimore)       Date:  2017-10       Impact factor: 1.889

Review 10.  Transverse myelitis.

Authors:  Shin C Beh; Benjamin M Greenberg; Teresa Frohman; Elliot M Frohman
Journal:  Neurol Clin       Date:  2013-02       Impact factor: 3.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.